A multifunctional DNA origami as carrier of metal complexes to achieve enhanced tumoral delivery and nullified systemic toxicity

Huang, Yanyu; Huang, Wei; Chan, Leung; Zhou, Binwei; Chen, Tianfeng

doi:10.1016/j.biomaterials.2016.06.053

Cited by 106 publications

(101 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…308–311 These Ru(II) complex, functionalized-nanomaterials were safety and efficacious. Although further research, including clinical studies, is needed to verify these results, these examples serve as the basis of new developments for treating cancer.…”

Section: Ruthenium(ii)-based Nanomaterials Systemsmentioning

confidence: 99%

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

et al. 2017

View full text Add to dashboard Cite

Cancer is rapidly becoming the top killer in the world. Most of the FDA approved anticancer drugs are organic molecules, while metallodrugs are very scarce. The advent of first metal based therapeutic agent, cisplatin, launched a new era in the application of transition metal complexes for therapeutic design. Due to their unique and versatile biochemical properties, ruthenium-based compounds have emerged as promising anti-cancer agents that serve as alternatives to cisplatin and its derivertives. The ruthenium(III) complexes have successfully been used in clinical research and their mechanisms of anticancer action have been reported in large volumes over the past few decades. Ruthenium(II) complexes have also attracted significant attention as anticancer candidates; however, only few of them have been reported comprehensively. In this review, we discuss the development of ruthenium(II) complexes as anticancer candidates and biocatalysts, including arene ruthenium complexes, polypyridyl ruthenium complexes, and ruthenium nanomaterial complexes. This review focuses on the likely mechanisms of action of ruthenium(II)-based anticancer drugs and the relationship between their chemical structures and biological properties. This review also highlights the catalytic activity and the photoinduced activation of ruthenium(II) complexes, their targeted delivery, and their activity in nanomaterial systems.

show abstract

Section: Ruthenium(ii)-based Nanomaterials Systemsmentioning

confidence: 99%

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Therefore, designing long-life Ru-based antineoplastic agents is the primary goal to overcome this limitation, and nanostructured materials functionalized with Ru complexes serve as one of the alternatives for targeted drug delivery. [32][33][34][35] A recent study by Huang et al showed that the antitumor efficacy of RuPOPs could be enhanced by using cancer-targeted DNA origami as a biocompatible nanocarrier. Under this condition, the formation of unique tetrahedral nanostructure of DNA cages effectively enhanced the partial intercalation of RuPOP, thus increasing the drug-loading efficacy.…”

Section: Recent Developments In Nanostructured Materials Functionalizmentioning

confidence: 99%

“…Therefore, this study demonstrates a strategy for the development of biocompatible and cancer-targeted DNA origami with enhanced anticancer efficacy and reduced toxicity for next-generation cancer therapy. 32 A novel pH-sensitive nanocapsule was recently shown to effectively deliver tris(1,10-phenanthroline) Ru(II) complex (3P-Ru) into glioma cells. In this study, delivery of 3P-Ru using the pH-sensitive nanocarrier significantly inhibited cell growth in both in vitro and in vivo models.…”

Section: Recent Developments In Nanostructured Materials Functionalizmentioning

confidence: 99%

Recent developments in the nanostructured materials functionalized with ruthenium complexes for targeted drug delivery to tumors

Thangavel

Viswanath

Kim

2017

IJN

View full text Add to dashboard Cite

In recent years, the field of metal-based drugs has been dominated by other existing precious metal drugs, and many researchers have focused their attention on the synthesis of various ruthenium (Ru) complexes due to their potential medical and pharmaceutical applications. The beneficial properties of Ru, which make it a highly promising therapeutic agent, include its variable oxidation states, low toxicity, high selectivity for diseased cells, ligand exchange properties, and the ability to mimic iron binding to biomolecules. In addition, Ru complexes have favorable adsorption properties, along with excellent photochemical and photophysical properties, which make them promising tools for photodynamic therapy. At present, nanostructured materials functionalized with Ru complexes have become an efficient way to administer Ru-based anticancer drugs for cancer treatment. In this review, the recent developments in the nanostructured materials functionalized with Ru complexes for targeted drug delivery to tumors are discussed. In addition, information on “traditional” (ie, non-nanostructured) Ru-based cancer therapies is included in a precise manner.

show abstract

“…33 We incubated MG-63 cells (80 nM) of LysoTracker DND-99 (SigmaAldrich) in 2 cm incubator dishes for 2 hours until 70% staining confluence had been reached. Then, 1 mg/mL of DAPI H33258 (Sigma-Aldrich) was added for 30 minutes, cells rinsed with PBS three times and incubated with 20 μM coumarin-6-loaded Tf-NGO@Pt for different periods, and observed by fluorescence microscopy.…”

Section: Tf-ngo@pt Intracellular Traffickingmentioning

confidence: 99%

Transferrin-functionalized nanographene oxide for delivery of platinum complexes to enhance cancer-cell selectivity and apoptosis-inducing efficacy

Zhu¹,

Zhou²,

Chan³

et al. 2017

IJN

Self Cite

View full text Add to dashboard Cite

Rational design and construction of delivery nanosystems for anticancer metal complexes is a crucial strategy to improve solubility under physiological conditions and permeability and retention behavior in tumor cells. Therefore, in this study, we designed and synthesize a transferrin (Tf)-conjugated nanographene oxide (NGO) nanosystem as a cancer-targeted nanocarrier of Pt complexes (Tf-NGO@Pt). This nanodelivery system exhibited good solubility under physiological conditions. Moreover, Tf-NGO@Pt showed higher anticancer efficacy against MCF human breast cancer cells than the free Pt complex, and effectively inhibited cancer-cell migration and invasion, with involvement of reactive oxygen species overproduction. In addition, nanolization also enhanced the penetration ability and inhibitory effect of the Pt complex toward MCF7 breast cancer-cell tumor spheroids. The enhancement of anticancer efficacy was positively correlated with increased cellular uptake and cellular drug retention. This study provides a new strategy to facilitate the future application of metal complexes in cancer therapy.

show abstract

A multifunctional DNA origami as carrier of metal complexes to achieve enhanced tumoral delivery and nullified systemic toxicity

Cited by 106 publications

References 52 publications

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

Recent developments in the nanostructured materials functionalized with ruthenium complexes for targeted drug delivery to tumors

Transferrin-functionalized nanographene oxide for delivery of platinum complexes to enhance cancer-cell selectivity and apoptosis-inducing efficacy

Contact Info

Product

Resources

About